Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients

Delfino, Vinícius Daher Alvares; Vianna, Areuza Célia de Andrade; Mocelin, Altair Jacob; Barbosa, Décio Sabbatini; Mise, Rosana Aiko; Matsuo, Tiemi

doi:10.1016/j.nut.2007.01.002

Cited by 50 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our findings, folate supplementation (5 mg/d) for 8 months in patients with T2DM led to increased TAC and decreased MDA levels . Furthermore, a significant increase in serum TAC with no effect on hydroperoxide levels was also seen following the administration of folate (10 mg daily) to haemodialysis patients after 6 months . The same findings have also been observed among adults with hypercholesterolaemia who were taking 5 mg folate daily for 8 weeks as well as in patients with T2DM who were taking 10 mg folate daily for 3 months .…”

Section: Discussionsupporting

confidence: 90%

The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled clinical trial

Bahmani

Karamali

Shakeri

et al. 2014

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled clinical trial

Bahmani

Karamali

Shakeri

et al. 2014

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Adding vitamin B 12 reduces plasma Hcy level further. Routine supplementations with folic acid and other antioxidant vitamins should be considered in HD patients to lower Hcy levels; although these supplements may not normalize the Hcy level, lowering the Hcy level may be beneficial by reducing the cardiovascular risk in this group [50, 137, 138]. Folic acid can lower the frequency of micronuclei in PBL in vitro [139]; micronuclei frequency was lowered by 6-month folic acid supplementation [140].…”

Section: Antioxidant Therapies To Reduce Oxidative Stress and Nuclmentioning

confidence: 99%

Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease

Sung

Hsu

Chen

et al. 2013

Oxidative Medicine and Cellular Longevity

162

110

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity and a high risk for developing malignancy. Excessive oxidative stress is thought to play a major role in elevating these risks by increasing oxidative nucleic acid damage. Oxidative stress results from an imbalance between reactive oxygen/nitrogen species (RONS) production and antioxidant defense mechanisms and can cause vascular and tissue injuries as well as nucleic acid damage in CKD patients. The increased production of RONS, impaired nonenzymatic or enzymatic antioxidant defense mechanisms, and other risk factors including gene polymorphisms, uremic toxins (indoxyl sulfate), deficiency of arylesterase/paraoxonase, hyperhomocysteinemia, dialysis-associated membrane bioincompatibility, and endotoxin in patients with CKD can inhibit normal cell function by damaging cell lipids, arachidonic acid derivatives, carbohydrates, proteins, amino acids, and nucleic acids. Several clinical biomarkers and techniques have been used to detect the antioxidant status and oxidative stress/oxidative nucleic acid damage associated with long-term complications such as inflammation, atherosclerosis, amyloidosis, and malignancy in CKD patients. Antioxidant therapies have been studied to reduce the oxidative stress and nucleic acid oxidation in patients with CKD, including alpha-tocopherol, N-acetylcysteine, ascorbic acid, glutathione, folic acid, bardoxolone methyl, angiotensin-converting enzyme inhibitor, and providing better dialysis strategies. This paper provides an overview of radical production, antioxidant defence, pathogenesis and biomarkers of oxidative stress in patients with CKD, and possible antioxidant therapies.

show abstract

“…Although plasma homocysteine level was reduced by 25% in folate-treated subjects compared to the placebo group, no significant changes were observed in markers of oxidant stress. A study by Alvares-Delfino and coworkers examined the effects of folate in patients with end-stage kidney disease on dialysis [60]. The authors reported that folic acid treatment normalized plasma homocysteine levels and increased plasma antioxidant capacity; however, hydroperoxide levels did not change.…”

Section: Clinical Evidence Connecting the Methionine-homocysteine mentioning

confidence: 99%

Methoxistasis: Integrating the Roles of Homocysteine and Folic Acid in Cardiovascular Pathobiology

Joseph

Loscalzo

2013

Nutrients

View full text Add to dashboard Cite

Over the last four decades, abnormalities in the methionine-homocysteine cycle and associated folate metabolism have garnered great interest due to the reported link between hyperhomocysteinemia and human pathology, especially atherothrombotic cardiovascular disease. However, clinical trials of B-vitamin supplementation including high doses of folic acid have not demonstrated any benefit in preventing or treating cardiovascular disease. In addition to the fact that these clinical trials may have been shorter in duration than appropriate for modulating chronic disease states, it is likely that reduction of the blood homocysteine level may be an oversimplified approach to a complex biologic perturbation. The methionine-homocysteine cycle and folate metabolism regulate redox and methylation reactions and are, in turn, regulated by redox and methylation status. Under normal conditions, a normal redox-methylation balance, or “methoxistasis”, exists, coordinated by the methionine-homocysteine cycle. An abnormal homocysteine level seen in pathologic states may reflect a disturbance of methoxistasis. We propose that future research should be targeted at estimating the deviation from methoxistasis and how best to restore it. This approach could lead to significant advances in preventing and treating cardiovascular diseases, including heart failure.

show abstract

Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients

Cited by 50 publications

References 32 publications

The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled clinical trial

The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled clinical trial

Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease

Methoxistasis: Integrating the Roles of Homocysteine and Folic Acid in Cardiovascular Pathobiology

Contact Info

Product

Resources

About